by The global Buccal Drug Delivery market size is expected to be worth around US$ 8.9 billion by 2030, according to a new report by Vision Research Reports.
The global Buccal Drug Delivery market size was valued at US$ 6.8 billion in 2020 and is anticipated to grow at a CAGR of 10.2% during forecast period 2021 to 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38999
Growth Factors
Buccal drug delivery systems have gained significant momentum since the last decade. Elimination of first-pass metabolism, quick absorption of the pH-sensitive drug, no interaction with stomach acid, quicker onset of action than any oral dose, minimal side effects, and reduced drug degradation are some of the factors fueling the market growth. Buccal drug delivery has gained large acceptance among geriatric patients and patients having difficulty swallowing.
Buccal drug delivery systems have gained significant growth potential due to constant research and development in this field. Compared to oral dosage form, buccal delivery is considered the most convenient and preferred choice, especially among geriatricpatients. This drug delivery route ensures elimination of first pass metabolism, allowing drugs thatarepH sensitive and easily degraded to be administered effectively.
Report Coverage
| Report Scope | Details |
| Market Size | US$ 8.9 billion by 2030 |
| Growth Rate | CAGR of 10.2% From 2021 to 2030 |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Type, Application, End-user |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Teva Pharmaceutical Industries Ltd.; Pfizer Inc.; GlaxoSmithKline plc; Indivior Pharmaceuticals; Generex Biotechnology; Catalent; ARx LLC; BioDelivery Sciences International, Inc.; Cynapsus Therapeutics Inc.; Endo Pharmaceuticals plc |
By Type Analysis
The buccal tablets and lozenges segment captured the largest share of over 45.0% in 2020. Increased consumer acceptance, ease of formulation, cost-effectiveness, and wide availability of drug candidates for formulation are the factors responsible for the segment growth.
The sublingual films segment is expected to grow at the highest rate during the forecast period. Factors such as immediate availability of high concentration of drug at a target site and increased research to develop controlled release formulation are responsible for the high growth of the segment.
By End-user Analysis
The hospitals segment dominated the market with a share of over 40.0% in 2020. Increased admission in hospitals, especially of geriatric patients, the abundance of emergency care supplies, and product development and research by various community hospitals are the reasons behind this segment growth.
3 community hospitals in Japan conducted in vitro and in vivo studies to develop mucoadhesive microparticle-laden gels for oral mucositis. The result confirmed the high concentration of the drug at the target site and quicker treatment than traditional dosage forms are likely to improve the adoption.
By Application Analysis
The smoking cessation segment accounted for the largest share of over 31.0% in 2020. Buccal drug delivery is often the most preferred and effective formulation for treating patients with smoking or nicotine addiction.
Increased research to treat sudden cardiac arrest outside hospitals and growing adoption of immediate treatment options have improved the acceptance of sublingual tablets, films, or even injections. This is responsible for the highest growth rate of the angina pectoris segment.
By Regional Analysis
North America dominated the market with a revenue share of over 31.0% in 2020. The presence of a large number of market players, improved research to identify suitable drug candidates, significant investment by large players to improve the development of newer formulations, and improved rate of diagnosis and treatment are the factors boosting the regional market growth.
Asia Pacific is expected to witness the highest growth during the forecast period. A rise in the geriatric population, the growth of the pharmaceutical industry, and an enormous rise in domestic players are likely to boost the regional market growth.
Key Players
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- GlaxoSmithKline plc.
- Indivior Pharmaceuticals
- Generex Biotechnology
- Catalent
- ARx LLC
- BioDelivery Sciences International, Inc.
- Cynapsus Therapeutics Inc.
- Endo Pharmaceuticals plc
Market Segmentation
- By Type
- Sublingual Films
- Buccal Tablets and Lozenges
- Oral Sprays
- By Application
- Pain Management
- Smoking Cessation
- Angina Pectoris
- Others
- By End-user
- Hospitals
- Ambulatory Centers
- Others
- Regional
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Norway
- Sweden
- Russia
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- Turkey
- UAE
- North America
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Buccal Drug Delivery Market, By Type
7.1. Buccal Drug Delivery Market, by Type, 2021-2030
7.1.1. Sublingual Films
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Buccal Tablets and Lozenges
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Oral Sprays
7.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Buccal Drug Delivery Market, By Application
8.1. Buccal Drug Delivery Market, by Application, 2021-2030
8.1.1. Pain Management
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Smoking Cessation
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Angina Pectoris
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Buccal Drug Delivery Market, By End User
9.1. Buccal Drug Delivery Market, by End User, 2021-2030
9.1.1. Hospitals
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Ambulatory Centers
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Buccal Drug Delivery Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Type (2017-2030)
10.1.2. Market Revenue and Forecast, by Application (2017-2030)
10.1.3. Market Revenue and Forecast, by End User (2017-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.1.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.1.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.1.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.1.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Type (2017-2030)
10.2.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.2.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.2.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Type (2017-2030)
10.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.6.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Type (2017-2030)
10.2.7.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.7.3. Market Revenue and Forecast, by End User (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Type (2017-2030)
10.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.3.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.3.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Type (2017-2030)
10.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.6.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Type (2017-2030)
10.3.7.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.7.3. Market Revenue and Forecast, by End User (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.4.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.4.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Type (2017-2030)
10.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.6.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Type (2017-2030)
10.4.7.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.7.3. Market Revenue and Forecast, by End User (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.5.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.5.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.5.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.5.5.3. Market Revenue and Forecast, by End User (2017-2030)
Chapter 11. Company Profiles
11.1. Teva Pharmaceutical Industries Ltd.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Pfizer Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. GlaxoSmithKline plc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Indivior Pharmaceuticals
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Generex Biotechnology
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Catalent
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. ARx LLC
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. BioDelivery Sciences International, Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Cynapsus Therapeutics Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Endo Pharmaceuticals plc
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38999
Contact Us:
Vision Research Reports
Call: +1 9197 992 333
